Introduction {#Sec1}
============

Paroxysmal dyskinesias (PxDs) are characterized by recurrent episodes of abnormal involuntary movements \[[@CR1]\]. The movement disorder may clinically present as dystonia, chorea, ballism or a mixture of these \[[@CR2]\]. Attacks often begin in childhood \[[@CR3]\]. A classification scheme distinguishes four subtypes: paroxysmal kinesigenic (PKD), non-kinesigenic (PNKD), exertion-induced (PED) and hypnogenic dyskinesia (PND) \[[@CR2]\].

In PKD, the most frequent form, attacks are precipitated by voluntary movements and usually last less than 5 min \[[@CR4]\]. Familial PKD inherits in an autosomal dominant mode with reduced penetrance \[[@CR3]\]. Infantile convulsions (IC) were frequently observed in the same pedigree and PKD and ICCA (IC with choreoathetosis) are now considered the same disorder \[[@CR5]--[@CR9]\]. Recently, the *PRRT2* gene was shown to cause familial PKD \[[@CR10]--[@CR16]\]. A quarter of PKD cases are sporadic. Several observations suggested that sporadic and familial forms may be etiologically distinct, featuring a higher number of attacks per day and an increased co-occurrence of migraine in sporadic patients (full reference list in Online Resource 1).

In PNKD attacks are triggered by alcohol, caffeine, fatigue or excitement \[[@CR2]\]. Attacks typically last minutes to 4 h. Mutations in the *MR*-*1* gene have been detected in several families \[[@CR17], [@CR18]\]. Clonazepam or other benzodiazepines can be helpful in some *MR*-*1* mutation carrier patients \[[@CR19]\].

PED is triggered by prolonged physical exercise \[[@CR20]\]. The symptom duration varies from 5--30 min \[[@CR1], [@CR3]\]. Few families have been described \[[@CR21]--[@CR24]\] as well as some sporadic patients \[[@CR25], [@CR26]\]. In some families epilepsy or migraine co-occur. In nine families with PED and epilepsy, mutations were found in the *SLC2A1* gene encoding the glucose transporter GLUT1 \[[@CR27], [@CR28]\].

Here we investigated a cohort of 33 Dutch PxD patients and found *PRRT2* frameshift mutations in both familial and sporadic cases of PKD. Furthermore, the majority of sporadic PxD cases as well as one PKD family did not carry mutations in *PRRT2*, *MR*-*1* or *GLUT1*, suggesting a contribution of additional genes or non-coding mutations.

Subjects and methods {#Sec2}
====================

This study was performed in accordance with the ethical standards laid down in the 1964 declaration of Helsinki and was approved by the Institutional Review Board of the VU Medical Center (\#2009/174). Informed written consent was obtained from all participating subjects. All patients with PxD in the Academic Medical Center (AMC), diagnosed between 1996 and 2010 were asked to participate . All participants completed a standardised questionnaire including age at onset, frequency, duration, triggers, symptoms during attacks, precipitating and alleviating factors, symptoms after an attack and family and medical history. Medical records EEG (electro-encephalogram, if achieved) and imaging reports were reviewed. In PKD families some unaffected family members were also examined. For genetic analysis, we collected venous blood samples (adults) or sputum (children). Genomic DNA was isolated using the PureGene Blood core kit (Qiagen). For familial cases, co-seggregation of the phenotype with chromosome 16 was confirmed using 23 microsatellite repeats (see Online Resource 2). PCR amplification of target genes was performed using primers specified in Online Resource 3. Products were sequenced using BigDyeTerminator v3.1 reagents and analyzed in a ABI Prism 3137 genetic analyzer. All patients were tested for *PRRT2*. Patients with PKD or PED were also tested for mutations in *GLUT1*. PNKD patients were also tested for *MR*-*1* gene mutations.

Results {#Sec3}
=======

Patients {#Sec4}
--------

Thirty-three PxD patients were detected and 23 volunteered to participate. Sixteen patients met the criteria for PKD including seven patients with a positive family history (Table [1](#Tab1){ref-type="table"}). The average age at onset was 14.1 years (ranging from 0 to 51) and did not differ significantly between familial and sporadic cases (12.4 and 15.4 years, respectively). There is a male predominance (63 %). Dystonia was observed in 88 % of the patients, whereas 31 % exhibited chorea. Combined dystonia and chorea was observed in 25 % of the patients. Seven patients tried carbamazepine and all experienced good control of complaints. Accompanying ailments were IC, epilepsy, migraine and tremor. It should be noted that IC were only present in the familial group.Table 1Clinical characteristics for familial/sporadic PxD cases studied and observed *PRRT2* mutationsPatientPxDSexAaO (years)InducerDystonia/choreaDurationFrequencyLocalisationEEGMigraineMedication*PRRT2* mutationOther genes testedFam. 1, II-2PKDF14Movement changeD+C7--30 sDailyLeft sidedN/A--Nonec.649dupC p.R217PfsX7Fam. 1, II-3PKDM15Movement changeD+C10 s10× per dayLeft sidedN/A--CBZ: good effectc.649dupC p.R217PfsX7*GLUT1*Fam. 2, IV-2PKDM8Sudden movementD5--15 s1--2× per dayLeft sidedN/A--CBZ: good effectNoneFam. 2, III-1PKDF10Sudden movementD10--15 sWeeklyRight sidedN/A--DPhT: moderate effectNoneFam. 2, II-4PKDM10Sudden movementD10 sN/ARight armN/A--NoneNoneFam. 3, III-1PKDM15Sudden movementD10 sDailyLeft legEpilepsy--CBZ: good effectc.649C\>T p.R217X*GLUT1*Fam. 3, II-4PKDM15Sudden movementD10--15 s3× per weekLeft sidedNormal--Nonec.649C\>T p.R217X1, SporadicPKDF3PlayingDMinutesDailyRight sidedNormal--NoneNo DNA2, SporadicPKDF0Movement changeD+C1.5 minSeveral per dayGeneralizedNormal--Nonec.3698T\>C in 3′UTR*GLUT1*3, SporadicPKDF51WalkingC1 s2--10× per dayBoth legsNormal--CBZ: good effectNone*GLUT1*, *MR*-*1*4, SporadicPKDM13Sudden movementD10 s1--2× per dayRight sidedN/A--CBZ: good effectc.649delC p.R217PfsX125, SporadicPKDM14Start of movementD+C15 s10× per dayAlternating sidesN/A--CBZ: good effectNone*GLUT1*, *MR*-*1*6, SporadicPKDM11Movement changeD10 s --1 min1--2× per dayGeneralizedN/A--CBZ: good effectc.649dupC p.R217PfsX77, SporadicPKDF29Small changes of movementCSeconds--minutesSeveral per dayLeft armNon-epileptiform PT abnormalitiesYesTBZ: moderate effectNone*GLUT1*, *MR*-*1*8, SporadicPKDM12Sudden movementD10--20 s5× per dayRight sidedN/A--NoneNone*GLUT1*, *MR*-*1*9, SporadicPKDM6N/AD\<1 minDailyGeneralizedNormalYesDPK: good effectNo DNA10, SporadicPNKDF0No clear inducersD+CMinutesN/AGeneralizedNormalYesCBZ, BDZ, DPK, DPhT: moderate effectNone*MR*-*1*11, SporadicPNKDF0Physical exercise, coldDSeveral hoursDaily--weeklyGeneralizedSuspect for epilepsy--BDZs, unknown effectNone*MR*-*1*12, SporadicPNKDF9FatigueDMinutes to hoursSeveral a monthRight sidedN/AYesDPK, lot of side effectsNone*MR*-*1*13, SporadicPNKDM10No clear inducersD30 minDailyRight sidedNormal--Anti-PD medication, CBZ, BDZ: no effectNone*MR*-*1*14, SporadicPEDF16Prolonged exerciseDUp to 3 h7× per quarterRight armPED-like--ClobazamNone*GLUT1*, *MR*-*1AaO* age at onset, *PT* pariotemporal, *CBZ* carbamazepine, *TBZ* tetrabenazide, *DPhT* diphantoine, *DPK* depakine, *PD* Parkinsons disease

The first family of Indonesian descent (Fig. [1](#Fig1){ref-type="fig"}) contains two patients with PKD, one with IC and one with migraine. The index patient (II-2), a 37-year-old woman, reported attacks of 10 s or less since the age of 12 years. Attacks consisted of a right-sided dystonic posture of her neck, jaw, hand, arm and leg. She experienced a preceding sensation and could abort attacks, the frequency of which decreased without medication. Her younger brother (III-3) had an identical phenotype. His attacks stopped with carbamazepine (50 mg per 2 days). Her daughter (IV-2) had IC without EEG abnormalities at the age of 6 months. In the past her mother (I-2) had migraine.Fig. 1Pedigrees with familial PKD. Convulsions co-occurred in all families

The second family consists of three PKD patients of Dutch origin. The index patient (IV-2), a 13-year-old boy had paroxysms since the age of 10 years after switching from rest to action. The attacks consisted of dystonic posture of his left arm followed by his mouth and leg. He had tremors of the hands and sudden involuntary movement of his neck. The patient experienced a preceding sensation and could abort an attack. The attacks presented less than five times a day, lasted 10--15 s and ceased with carbamazepine (50 mg dd). His mother (III-1) experienced similar attacks in her youth (10--20 years). She also reported a febrile convulsion at 1 year of age. The grandfather (II-4) had similar attacks when he was young and also exhibited tremors of the hands. A great-uncle (II-1) also experienced involuntary movements, but specifics were not possible to collect. The older brother (IV-1) had a febrile convulsion at 1 year of age.

The third family includes two PKD patients. The index patient (III-1) had PKD since age 15 years. The attack consisted of left-sided slow kicking movements causing him to fall. Occasionally a sensory warning preceded the attack, but he was unable to prevent attacks. They stopped with carbamazepine (2 dd 200 mg). He was previously diagnosed with benign familial infantile convulsions (BFIC) treated with valproic acid, and had a single generalized tonic--clonic seizure at age 13 years and twice again at age 14 years. Interictal EEG showed series of epileptic discharges over the right frontocentral area, especially during drowsiness and hyperventilation \[[@CR29]\]. Considering the PKD and seizures, the diagnosis ICCA was made.

Besides PKD patients, our cohort contained four sporadic PNKD patients and one female PED patient. The average onset age of PNKD was 4.75 (0--10) years similar to previous findings \[[@CR1], [@CR26], [@CR30]\]. Again, dystonia was the most common expression. Two patients tried carbamazepine without effect. Two patients had migraine. The female PED patient had isolated dystonia. Complaints started at age 16 years; attacks gradually decreased and she had her last attack at age 23 years. During an attack she took clobazam to stop the complaints. It is common to have no family history for PED \[[@CR26]\].

Several patients underwent a brain CT-scan or MRI (Table [1](#Tab1){ref-type="table"}). All were normal. Only in the PED patient three small lacunar lesions appeared in the right sided basal ganglia, especially the global pallidus and adjacent to the internal capsule. In EEG registrations, most of the patients showed no epileptic discharges. Clinical epilepsy was confirmed by neurophysiological investigation in only one PKD patient (III-1 of family 3) (Table [1](#Tab1){ref-type="table"}). In a patient with PNKD and mental retardation an EEG showed indications for epilepsy, but clinically no convulsions ever occurred.

Mutation detection {#Sec5}
------------------

For familial PKD, *PRRT2* mutations have been observed in multiple Han Chinese families \[[@CR10]--[@CR13], [@CR16], [@CR31]\]. Consistently, we observed *PRRT2* mutations in family 1 (c.649dupC) and 3 (c.649C\>T, introducing an opal stop codon replacing proline 217). In family 2 we did not find any mutation, although the phenotype co-seggregated with a region of chromosome 16p distal from marker D16S685 (see Online Resource 2).

In addition, two sporadic PKD patients carried frameshift mutations in *PRRT2* (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}) c.649delC (patient 4) and c.649dupC (patient 6). Another variation, c.3698T\>C, was observed in the 3′UTR in exon 4. Although this variation is not reported in dbSNP or the 1,000 genome database it is not predicted to have major effects on *PRRT2* gene function.Fig. 2Sequence traces of observed *PRRT2* mutations. *Top trace* indicates the wildtype sequence and the corresponding open reading frame. *Arrows* indicate mutated residues

Six out of nine cases of sporadic PKD were not associated with mutations in *PRRT2*. We also did not detect mutations in other candidate genes tested including *MR*-*1* (known to cause PNKD) and *GLUT1* (known to cause PED and sporadic PKD) \[[@CR32]\].

Discussion {#Sec6}
==========

We investigated the clinical and genetic aspects of 21 PxD patients seen over the last 15 years in our third opinion movement disorder out-patient clinic. This cohort comprised 16 patients with PKD, four with PNKD and one with PED. Familial PKD co-seggregated with the known locus in all pedigrees. *PRRT2* truncating mutations were identified in two families and two sporadic cases.

In our study 53 % of the PKD patients were sporadic cases, whereas only 4.8 % of published cases were sporadic \[[@CR4], [@CR33]\]. Possibly sporadic forms are underrepresented, because linkage and gene identification studies preferentially focussed on familial forms. Other clinical aspects of patients in our cohort were similar to those of in total 681 published PKD patients (see Online Resource 1). The mean age at onset was similar (10.4 years on average) and as in our cohort, dystonia was also the most common movement disorder in literature (seen in 43 % of patients). Both in literature (30 %) and in our findings PKD and IC are correlated, especially in the familial forms \[[@CR9]\].

The clinical features of sporadic and familial PKD patients were similar, although IC were observed only in the familial group. Migraine occurred in two of nine sporadic PKD cases and in one PRRT2 mutation carrier in family 1 (I-2). The attacks were preceded by an aura in 93 % of sporadic patients and in all adult familial patients questioned.

Despite the previous idea that sporadic and familial PKD represent distinct diseases, we observed identical mutations in sporadic and familial PKD \[[@CR11]--[@CR13]\]. This is consistent with a recent study \[[@CR16]\]. A pseudo-sporadic occurrence is not surprising in view of the reduced penetrance of familial PKD combined with the variable clinical expression that includes IC, BFIC and migraine \[[@CR14], [@CR15]\].

The lack of *PRRT2* mutations in four out of seven sporadic cases from our cohort suggests that additional PKD genes exist. In another recent study, seven out of eight sporadic cases were negative for *PRRT2* mutations \[[@CR16]\]. Similarly, familial PKD cases occur without *PRRT2* mutations both in our study and previous investigations \[[@CR16]\]. This suggests a contribution of other genes which may co-segregate with the same locus as *PRRT2* or alternatively of non-coding mutations that may affect *PRRT2* gene function.
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